Browse the list of Consortia below to learn more about each CAVD Grant.
Ackerman/Alter: Leveraging Antibody Effector Function Alt: Physiologically Relevant and Rapidly Generated HIV-1 Vaccine Mouse Models Alter: A Generic Approach to Optimizing the Antigenicity of HIV-1 Envelope Immunogens Alter: Defining Signatures of Antibody Responses that Correlate with Protection to Develop Down-Selection Criteria to Guide Vaccine Candidate Selection
Baker: Testing the Nearest Neighbor Approach to Active Vaccination for HIV-1 bNAbs Barouch: Epitope-Modified Env Trimers for Induction of Heterologous Tier 2 NAbs Barouch: Therapeutic Efficacy of Potent Broadly Neutralizing mAbs for HIV-1 Eradication Busch: Validation of Existing and Ultra-Sensitive Assays for Qualifying HIV Persistence
Return to top
Ciaramella: mRNA Encoded Abs for HIV Prophylaxis Corey: Support for HVTN 702
Farzan: Preventing HIV-1 transmission with eCD4-Ig Feinberg: IAVI Neutralizing Antibody Consortium
Gallo: FLSC Phase I & II Clinical Trials Gottardo: VISC
Hassell: Vaccine Product Development Center Hassell: Vaccine Product Development Center: GMP Manufacturing, Toxicology, and Clinical Data Management Haynes: Centralized Envelope Phase I Study Haynes: MPER-Peptide Liposome Immunogen Testing Haynes: Protein Expression Facility Ho: Engineered Bispecific bNAbs for Prevention Ho: First in human clinical evaluation of 10E8.4/iMab, a potent and broad bispecific antibody against HIV
Johnson: Single Cell Transcriptional Profiling of Latently-Infected CD4+ T Cells Jolicoeur: Development of a new class of immunogens for raising broadly neutralizing antibodies
Kay: Comparative NHP Study to Test New Capside Against AAV1 Koup: Cellular VIMC Kublin: HIV Vaccine Trials Site Development for the P5 Program Kublin: HVTN:100 Kublin: HVTN 705: A phase 2b clinical trial to evaluate the efficacy of Ad26 recombinant HIV vaccine + gp140
Lemon: CAVD Alliance Management Lewis: Ab Specificity & Fc-Mediated Protection
Masopust: Vaccination to prevent HIV Infection McElrath: Durability of HIV-speci c protective Ab responses in human immunology-based experimental medicine trials McMichael: HLA-E restricted CD8 responses induced by CMV vaccines Montefiori: Ab VIMC Moore: Next generation BG505 SOSIP.664-trimer based lineage HIV vaccines
Nolan: Technology Development for HIV Reservoir Characterization Nussenzweig: Clinical Trial of Broadly Neutralizing anti-HIV Antibodies Nussenzweig: Development of optimized broadly neutralizing antibodies for HIV-1 prevention Nussenzweig: Discovery & Characterization of bNAbs
Pantaleo: Poxvirus-Based Vaccine Development Pantaleo: RepliVax Vaccine Platform Parks: HIV Vaccine Clinical Candidates based on Replication-Competent Viral Vectors that Preferentially Replicate in Lymphoid Tissues Pettit: Just Biotherapeutics Support for HIV bNAbs Picker: An Attenuated CMV Vector Picker: MHC II and MHC E-Restricted CD8+ T Cells and Control of HIV Pulendran: Protective humoral responses against HIV
Reinherz: HIV clade C MPER immunogens eliciting 10E8-like speci cities
Shattock: DNA Vaccination for HIV Immunogen Discovery Shaw: Novel SHIV Designs to Elicit bNAbs and Guide Iterative Vaccine Development
Überla: Antibodies without HIV T helper cells
Walker: bNAbs after Infection and Immunization Walker: Implications for vaccine design from T and B cell mechanisms of HIV control Ward: Establishment of an Analytics Network to Support Qualified/Validated Assays Required for Characterization of HIV Env Immunogens